SEATTLE, Sept. 19, 2025 – HDT Bio Corporation has announced that the U.S. Food and Drug Administration (FDA) has cleared its Investigational New Drug (IND) application for HDT-321, a first-in-class prophylactic designed to protect against Crimean-Congo Hemorrhagic Fever (CCHF)—a highly lethal, tick-borne viral disease recognized as a top-priority global health threat. This milestone positions HDT-321 as the first clinical-stage product specifically targeting CCHF using a non-viral immune-stimulator platform.
Science Significance
CCHF is one of the world’s most widespread viral hemorrhagic fevers, with mortality rates reaching up to 40%. Transmitted by ticks or infected animals, the virus is listed by the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC) as a top-priority pathogen due to its outbreak potential and lack of approved treatments or vaccines. HDT-321 leverages HDT Bio’s proprietary LION™ delivery system, previously tested during the company’s COVID-19 vaccine program (HDT-301), which demonstrated strong immune activation and a favorable safety profile in human trials.
Regulatory Significance
The FDA’s IND clearance enables the initiation of human clinical trials in the United States, representing a crucial step toward bringing the world’s first CCHF prophylactic to market. The development is supported by the U.S. Department of Defense and the Medical CBRN Defense Consortium (MCDC), underscoring the vaccine’s national biodefense relevance. Cooperative preclinical testing with the National Institute of Allergy and Infectious Diseases (NIAID) and the University of Texas Medical Branch (UTMB) demonstrated that HDT-321 provided robust protection in multiple animal models.
Business Significance
Advertisement
This clearance validates HDT Bio’s immune-stimulator platform and strengthens its global health and biodefense portfolio. The company has a track record of rapid deployment: its LION™ platform enabled emergency-use authorized vaccines in India during the COVID-19 pandemic. The U.S. government’s backing positions HDT Bio to access significant funding opportunities and potential procurement contracts for pandemic preparedness and military defense. The successful clinical development of HDT-321 could establish HDT Bio as a leader in field-ready, American-made countermeasures for high-consequence infectious diseases.
Patients’ Significance
CCHF remains a serious and growing threat to both civilian populations and military personnel. In 2009, a U.S. soldier in Afghanistan died after contracting the virus, highlighting the disease’s risk to deployed forces. Recent cases in Portugal and Spain, coupled with climate-driven tick habitat expansion, raise concerns about future outbreaks in the United States. HDT-321 offers the promise of a scalable, non-viral vaccine that can be deployed without cold-chain infrastructure, providing vulnerable populations with a potentially life-saving preventive option.
Policy Significance
The FDA decision aligns with U.S. legislative efforts to combat tick-borne diseases, including the Kay Hagan Tick Act, which mandates a coordinated national strategy against pathogens like CCHF. It also supports the U.S. biodefense agenda by promoting domestic manufacturing and rapid-response technologies. HDT-321 demonstrates how public-private partnerships—spanning the Department of Defense, NIH, and academic institutions—can accelerate innovation to address both public health and national security priorities.
Transaction Highlights
The FDA’s Investigational New Drug (IND) clearance for HDT-321 is the result of an extensive public–private partnership that united HDT Bio with the National Institute of Allergy and Infectious Diseases (NIAID), the University of Texas Medical Branch (UTMB), and the U.S. Department of Defense. Under a Cooperative Research and Development Agreement (CRADA), NIAID’s Rocky Mountain Laboratories in Montana conducted preclinical studies demonstrating that HDT-321 provided strong protection against Crimean-Congo Hemorrhagic Fever (CCHF) in multiple animal models. The program is backed by the Medical CBRN Defense Consortium (MCDC) and the Department of Defense, reflecting its critical role in national biodefense. HDT-321 combines HDT Bio’s proprietary LION™ delivery platform, previously validated in COVID-19 vaccine trials, with newly discovered antigens specific to CCHF, enabling a scalable, non-viral, cold-chain–independent prophylactic. This regulatory milestone not only authorizes first-in-human trials but also validates HDT Bio’s broader immune-stimulator platform, strengthening its pipeline of infectious disease countermeasures and positioning the company for future government contracts and global commercialization opportunities.
Source: HDT Bio Corporation Press Release
